New 'T-Cell Engager' drug tested in men with Tough-to-Treat prostate cancer
NCT ID NCT03792841
Summary
This was an early safety study for a new drug called acapatamab, designed to help the body's own immune cells attack advanced prostate cancer. It involved 212 men whose cancer had spread and was no longer responding to standard hormone and chemotherapy treatments. The main goal was to find a safe dose and understand how the drug behaves in the body, while also checking for any early signs that it might help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
BC Cancer Vancouver
Vancouver, British Columbia, V5Z 4E6, Canada
-
Chris OBrien Lifehouse
Camperdown, New South Wales, 2050, Australia
-
City of Hope National Medical Center
Duarte, California, 91010, United States
-
City of Hope at Long Beach Elm
Long Beach, California, 90813, United States
-
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, 89169, United States
-
El Camino Hospital
Campbell, California, 95008, United States
-
Emory University
Atlanta, Georgia, 30322, United States
-
Erasmus Medisch Centrum
Rotterdam, 3015 GD, Netherlands
-
Indiana University
Indianapolis, Indiana, 46202, United States
-
Institut Gustave Roussy
Villejuif, 94805, France
-
Krankenhaus der Barmherzigen Brueder Wien
Vienna, 1020, Austria
-
Landeskrankenhaus Salzburg
Salzburg, 5020, Austria
-
Linkou Chang Gung Memorial Hospital of Chang Gung Medical Foundation
Taoyuan District, 33305, Taiwan
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
National Cancer Center Hospital East
Kashiwa-shi, Chiba, 277-8577, Japan
-
National Cancer Centre Singapore
Singapore, 169610, Singapore
-
National University Hospital
Singapore, 119074, Singapore
-
Ordensklinikum Linz Elisabethinen
Linz, 4020, Austria
-
Peter MacCallum Cancer Centre
Parkville, Victoria, 3050, Australia
-
Scientia Clinical Research Ltd
Randwick, New South Wales, 2031, Australia
-
Tulane Medical Center
New Orleans, Louisiana, 70112, United States
-
Universitaetsklinikum Allgemeines Krankenhaus Wien
Vienna, 1090, Austria
-
Universitair Ziekenhuis Gent
Ghent, 9000, Belgium
-
Universite Catholique de Louvain Cliniques Universitaires Saint Luc
Brussels, 1200, Belgium
-
University of California Los Angeles
Los Angeles, California, 90095, United States
-
University of Iowa Hospitals and Clinics
Iowa City, Iowa, 52242, United States
-
University of Texas Southwestern Medical Center
Dallas, Texas, 75390, United States
-
Washington University
St Louis, Missouri, 63110, United States
-
Weill Cornell Medical College
New York, New York, 10065, United States
-
Yokohama City University Medical Center
Yokohama, Kanagawa, 232-0024, Japan
Conditions
Explore the condition pages connected to this study.